Pharma BD Deal Intelligence
A $970M-$1B bet on a single Phase 3 asset—abiraterone—became Zytiga, peaking at $3.5B in annual sales (2018) and generating well over $15B cumulative revenue before patent expiry. One of oncology's highest-ROI acquisitions of its era, though patent litigation delays couldn't stop generics from cutting sales roughly in half by 2023.
A ~$970M-$1.0B bet on a single Phase 3 asset (abiraterone) became Zytiga — a drug that peaked at $3.5B in annual sales (2018) and generated well over $15B in cumulative revenue before patent expiry, making this one of the highest-ROI oncology acquisitions of its era.
Full analysis, sources & comparables →William Hait of Ortho Biotech Oncology framed abiraterone as a strategic anchor that would 'strengthen our growing capabilities toward a leadership position in…
Phase 3 COU-AA-301 demonstrated 14.8 vs 10.9 month median OS in docetaxel-pretreated mCRPC, leading to early trial unblinding and FDA approval April 2011.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$43/share tender; ~$894M equity + cash on hand = ~$970M. Acquired abiraterone (Zytiga) for prostate cancer. Closed Q3 2009. Source: J&J IR, SEC, Cravath, Fierce Biotech.
A ~$970M-$1.0B bet on a single Phase 3 asset (abiraterone) became Zytiga — a drug that peaked at $3.5B in annual sales (2018) and generated well over $15B in cumulative revenue before patent expiry, making this one of the highest-ROI oncology acquisitions of its era.
Assessment window: 15yr post-close.
334K US cases/yr
Prostate cancer is the most common non-skin cancer in American men, with castration-resistant disease (mCRPC) representing the lethal phase that emerges after androgen-deprivation therapy fails. Patients with metastatic disease have substantially worse prognosis (5-year survival ~40%) and historically had limited options once docetaxel chemotherapy failed.
When J&J agreed to buy Cougar Biotechnology in May 2009, the post-docetaxel mCRPC space was essentially empty. Sanofi-aventis's Jevtana (cabazitaxel) was still in registration, and Medivation/Astellas's MDV3100 (later Xtandi/enzalutamide) was years from approval. Cougar's lead asset abiraterone acetate (later Zytiga) was a first-in-class oral CYP17A1 inhibitor in two Phase 3 trials demonstrating ~4-month median OS extension (14.8 vs 10.9 months) post-chemo. Rodman & Renshaw analyst Simos Simeonidis called the 16% premium reasonable and flagged blockbuster potential pending survival data. The deal positioned J&J's Ortho Biotech oncology unit as a leader in the emerging novel hormonal agent (NHA) class. Zytiga was approved April 2011 and grew into a multi-billion-dollar franchise before facing enzalutamide competition and later generic erosion. The mCRPC landscape today includes Zytiga, Xtandi, Erleada, Nubeqa, Pluvicto (177Lu-PSMA), and PARP inhibitors (Lynparza, Talzenna) — a category that effectively did not exist when J&J bought Cougar.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Cougar Biotechnology, Inc. (this deal) | 2009 | $970M | 91 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 2009 deals · Johnson & Johnson deals